The United Kingdom and the United States have finalized a important commercial pact that will guarantee zero levies on UK pharmaceutical exports going into the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has committed to boost expenditure on pharmaceuticals through the National Health Service (NHS). This move ensures that duties on these key products will be held at zero for a timeframe of the next three years.
This deal is in response to recent threats to significantly raise duties on branded pharmaceutical imports, with increases mentioned reaching double the cost.
"This arrangement with the UK bolsters the worldwide climate for new treatments and establishes long-overdue fairness to U.S.–U.K. medicine commerce," a release noted.
Trade Importance
Drugs constitute one of the UK's most significant export categories to the United States, which is by far the primary buyer for leading UK drugmakers.
Statistics show that in the one-year period to the end of last September, the UK shipped medicines worth billions to the US. This value accounted for nearly one-fifth of total UK exports in that period.
"This guarantee safeguards jobs, stimulates investment and facilitates the UK to establish itself as a international leader for biotech and pharma," a minister commented.
Detailed British Pledges
The deal involves several specific commitments from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new therapies to be too expensive by 25%.
- Increased NHS Spending: There is a target to double total health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage drug companies must refund to the NHS to stay within budget will be restricted at 15%. In the past, refunds exceeded twenty percent.
Broader Context
This agreement comes amid a ongoing tension between the drug companies and the ministers over drug pricing and regulatory access.
These tensions were exacerbated by arguments that American customers were paying several times more for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar funding commitments have been announced toward American operations.
One official publicly accepted that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had declined as a percentage of its total funding over the previous ten-year period.
